Meta AnalysisID 1557
生物制剂、免疫调节剂和次水杨酸铋治疗显微镜下结肠炎的临床应答：系统评价与Meta分析
CRD42020218649
What is the effect of biologics (i.e. infliximab, adalimumab, golimumab, certolizumab, vedolizumab, ustekinumab or tocilizumab), immunomodulators (i.e. azathioprine or 6-mercaptopurine), and bismuth subsalicylate on clin
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1557
- Evidence Id
- 10115
- Core Evidence Id
- 10115
- Source Meta Analysis Id
- 1511
- Herb2 Meta Analysis Id
- HBMA001511
- Crd Id
- CRD42020218649
- Title
- Clinical response of biologics, immunomodulators and bismuth subsalicylate in microscopic colitis: a systematic review and meta-analysis
- Review Question
- What is the effect of biologics (i.e. infliximab, adalimumab, golimumab, certolizumab, vedolizumab, ustekinumab or tocilizumab), immunomodulators (i.e. azathioprine or 6-mercaptopurine), and bismuth subsalicylate on clinical response in microscopic colitis (i.e. lymphocytic- and collagenous colitis) as defined by included studies (e.g., reduction of stool frequency) assessed in a systematic review and meta-analysis.
- Study Type Included
- All study design will be included (including case series with more than 10 participants).
- Condition Being Studied
- Microscopic colitis (i.e. lymphocytic- and collagenous colitis).
- Participant
- Inclusion criteria: Adults (18+ years) with microscopic colitis (i.e. lymphocytic- and collagenous colitis).
- Animal
- Human Disease Modelled
- Intervention
- Studies are eligible for the present project if they include (at least) one treatment group in which either biologics, immunomodulators, and/or bismuth subsalicylate is administered for microscopic colitis.
- Comparator Control
- Not applicable
- Main Outcome
- Primary outcome measure: Clinical response as defined by included studies (i.e., reduction of stool frequency). Secondary outcomes: 1) Histological response as defined by included studies; 2) quality of life if assessed by a validated scoring system, and 3) the occurrence of any adverse events. Measures of effect Relative risk (RR) or odds ratio (OR) for cohort and case-control studies, and prevalence for case series included.
- Outcome Measure
- Additional Outcome
- None. Measures of effect Not applicable.
- Study Method
- Systematic review
- Keyword
- Biological Products; Bismuth; Colitis, Microscopic; Humans; Immunologic Factors; bismuth subsalicylate
- Contact
- Sebastian Kjaergaard [email protected]
- Organisational Affiliation
- Dept. of Gastroenterology D112, University of Copenhagen, Herlev Hospital https://www.herlevhospital.dk/
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Denmark
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-11-11
- Registration Date
- 2020-12-12
- Anticipated Start Date
- 2021-02-01
- Anticipated Completion Date
- 2021-08-31
- Title Cn
- 生物制剂、免疫调节剂和次水杨酸铋治疗显微镜下结肠炎的临床应答：系统评价与Meta分析
- Title En
- Clinical response of biologics, immunomodulators and bismuth subsalicylate in microscopic colitis: a systematic review and meta-analysis
- Bilingual Status
- complete